Dr. Oscar Lin, MD

Dr. Lin practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Lin's NPI, 1124008040, was assigned on January 18, 2006. Dr. Lin holds New York license 219084.

Dr. Lin's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Lin's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. Lin is also affiliated with Tisch Hospital. The medical group on file is Memorial Pathology Group. Dmand AI also links Dr. Lin to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 5 sites in all. Vendor and product names are available with a free account.

Anatomic pathology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207ZP0101X. Dr. Lin is licensed in New York.

CMS data shows 4,144 Medicare services from Dr. Lin across 22 procedure codes in 2024, for 1,603 Medicare patients. Medicare paid $134,779 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 1,603 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 726 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 65, with 47% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 77 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 68 papers to Dr. Lin, published from 2006 to 2025. 2016 was the busiest year, with 4. The most frequent topics are Urinary Bladder Neoplasms, Biomarkers, Tumor and Biopsy. Dr. Lin has published most often in Gynecol Oncol. Dr. Lin's most frequent co-authors are Guido Dalbagni, MD, Richard R. Barakat, MD and Bernard H. Bochner, MD.

CMS Open Payments shows 18 general payments to Dr. Lin from 2 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 99% of the total. Janssen Research & Development, LLC paid the most, $33,408.

Dr. Lin is in network with 3 carriers, including Excellus BlueCross BlueShield, CMS Medicare and NY State Medicaid. Medicare plans come from the most carriers, 2. Check the plan with the practice before a visit.